Daniel Virnich Buys 22,640 Shares of The Oncology Institute, Inc. (NASDAQ:TOI) Stock

The Oncology Institute, Inc. (NASDAQ:TOI) CEO Daniel Virnich bought 22,640 shares of Oncology Institute stock in a transaction on Wednesday, March 26th. The shares were purchased at an average cost of $1.04 per share, with a total value of $23,545.60. Following the acquisition, the chief executive officer now directly owns 724,363 shares of the company’s stock, valued at approximately $753,337.52. The trade was a 3.23 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Oncology Institute Price Performance

Shares of TOI traded up $0.03 during trading hours on Friday, hitting $1.14. 502,477 shares of the stock were exchanged, compared to its average volume of 699,326. The stock’s 50-day moving average price is $0.85 and its two-hundred day moving average price is $0.47. The Oncology Institute, Inc. has a 12-month low of $0.13 and a 12-month high of $1.78. The company has a debt-to-equity ratio of 5.91, a quick ratio of 2.27 and a current ratio of 2.49. The company has a market cap of $86.14 million, a price-to-earnings ratio of -1.46 and a beta of 0.41.

Oncology Institute (NASDAQ:TOI) last released its earnings results on Monday, March 24th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). The business had revenue of $100.27 million for the quarter, compared to analysts’ expectations of $109.15 million. Oncology Institute had a negative return on equity of 186.83% and a negative net margin of 17.63%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC increased its holdings in shares of Oncology Institute by 7.1% in the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock valued at $56,000 after purchasing an additional 12,000 shares during the last quarter. HighTower Advisors LLC raised its holdings in shares of Oncology Institute by 190.8% during the 3rd quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock worth $27,000 after acquiring an additional 53,382 shares during the period. Jane Street Group LLC boosted its position in shares of Oncology Institute by 613.6% during the 4th quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock valued at $39,000 after acquiring an additional 109,769 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Oncology Institute in the fourth quarter valued at about $41,000. Finally, Tiff Advisory Services LLC increased its position in Oncology Institute by 13.2% during the fourth quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company’s stock worth $921,000 after purchasing an additional 346,256 shares during the last quarter. 36.86% of the stock is owned by hedge funds and other institutional investors.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.